☆ 4.6 Article

Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals

CELL REPORTS MEDICINE (2021)

Related references

Note: Only part of the references are listed.

Article Immunology

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Annika Nelde et al.

Summary: SARS-CoV-2-specific T cell epitopes were identified in convalescent and unexposed individuals, showing cross-reactivity with common cold coronaviruses. The diversity of SARS-CoV-2 T cell responses may be associated with mild symptoms of COVID-19.

NATURE IMMUNOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Adaptive immunity to SARS-CoV-2 and COVID-19

Alessandro Sette et al.

Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.

CELL (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Tyler N. Starr et al.

Summary: Research has found that mutations in the receptor binding domain (RBD) of SARS-CoV-2 may potentially escape the action of the REGN-COV2 cocktail, providing important information for interpreting mutations observed during viral surveillance.

SCIENCE (2021)

Add to Collection

Article Cell Biology

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Anthony T. Tan et al.

Summary: This study found that early induction of interferon-gamma (IFN-gamma) secreting SARS-CoV-2-specific T cells was present in patients with mild disease and accelerated viral clearance, while rapid induction and quantity of humoral responses were associated with an increase in disease severity. These findings highlight the importance of early functional SARS-CoV-2-specific T cells in both vaccine design and immune monitoring.

CELL REPORTS (2021)

Add to Collection

News Item Critical Care Medicine

New variant of SARS-CoV-2 in UK causes surge of COVID-19

Tony Kirby

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Piyada Supasa et al.

Summary: Research on the UK-dominant variant B.1.1.7 shows that it is harder to neutralize than the parental virus, but widespread escape from antibodies or monoclonal antibodies has not been observed yet.

CELL (2021)

Add to Collection

Article Microbiology

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Xiaoying Shen et al.

Summary: Current COVID-19 vaccines target the ancestral SARS-CoV-2 spike, but the emerging B.1.1.7 variant with multiple spike mutations may impact some antibody therapies while posing no major concerns for vaccine efficacy or increased risk of reinfection.

CELL HOST & MICROBE (2021)

Add to Collection

Article Microbiology

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Allison J. Greaney et al.

Summary: The evolution of SARS-CoV-2 may impact the recognition of the virus by human antibody-mediated immunity, with mutations affecting antibody binding varying significantly among individuals and within the same individual over time. Despite this variability, mutations that greatly reduce antibody binding usually occur at specific sites in the RBD, with E484 being the most crucial. These findings can inform surveillance efforts for SARS-CoV-2 evolution in the future.

CELL HOST & MICROBE (2021)

Add to Collection

Letter Medicine, General & Internal

Emergence of a Novel SARS-CoV-2 Variant in Southern California

Wenjuan Zhang et al.

Summary: The research focused on sequencing and phylogenetic analyses of SARS-CoV-2 isolates from symptomatic patients at Cedar-Sinai Medical Center in November-December 2020, providing insights into a surge in cases and hospitalizations during that period.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Immunology

Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection

Nina Le Bert et al.

Summary: The efficacy of virus-specific T cells in clearing pathogens involves a delicate balance between antiviral and inflammatory responses. Asymptomatic individuals clearing SARS-CoV-2 showed increased production of IFN-gamma and IL-2, along with a proportional secretion of IL-10 and proinflammatory cytokines, while symptomatic individuals displayed a disproportionate secretion of inflammatory cytokines triggered by SARS-CoV-2-specific T cell activation.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Immunology

Persistent cellular immunity to SARS-CoV-2 infection

Gaelle Breton et al.

Summary: Recovered individuals exhibit persistent polyfunctional SARS-CoV-2 antigen-specific memory, as well as enduring alterations in the relative overall numbers of CD4(+) and CD8(+) memory T cells, including cell division and expression of activation/exhaustion markers.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Letter Virology

Genomic Characterization of a Novel SARS-CoV-2 Lineage from Rio de Janeiro, Brazil

Carolina M. Voloch et al.

JOURNAL OF VIROLOGY (2021)

Add to Collection

Letter Medicine, General & Internal

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Sharon Amit et al.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

Add to Collection

Article Immunology

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Jianmin Zuo et al.

Summary: The study shows that functional SARS-CoV-2-specific T cell responses are retained and robust at 6 months following infection, with higher T cell responses observed in donors who had experienced symptomatic infection. Levels of nucleoprotein-specific T cells were correlated with nucleoprotein-specific antibody levels, providing insights into the persistence and correlation of immune responses.

NATURE IMMUNOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Constantinos Kurt Wibmer et al.

Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Sixteen novel lineages of SARS-CoV-2 in South Africa

Houriiyah Tegally et al.

Summary: The study identified 16 new lineages of SARS-CoV-2 in South Africa between March and August 2020, with unique mutations not found elsewhere. Three lineages (B.1.1.54, B.1.1.56, and C.1) dominated during the country's first wave, accounting for approximately 42% of all infections. The C.1 lineage, with 16 nucleotide mutations including the D614G spike protein change, became the most geographically widespread by August 2020. Genomic surveillance played a crucial role in identifying the 501Y.V2 variant in South Africa in December 2020.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Kai Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Nicholas G. Davies et al.

Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Alexander Muik et al.

Summary: A new SARS-CoV-2 lineage B.1.1.7 has emerged in the UK, which is more transmissible and faster spreading than other strains. However, a study found that the BNT162b2 vaccine offers largely preserved protection against the B.1.1.7 lineage, despite some reduced neutralizing titers.

SCIENCE (2021)

Add to Collection

Article Microbiology

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Venkata Viswanadh Edara et al.

Summary: Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.

CELL HOST & MICROBE (2021)

Add to Collection

Article Medicine, General & Internal

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

Victoria Jane Hall et al.

Summary: The study aimed to determine the factors associated with vaccine coverage for two COVID-19 vaccines in the UK and to document the vaccine effectiveness of the BNT162b2 mRNA vaccine among healthcare workers. Results showed that the vaccine can prevent both symptomatic and asymptomatic infections in working-age adults, with a vaccine effectiveness of 70% after the first dose and 85% after the second dose.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary et al.

Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Sandile Cele et al.

Summary: The study compared the neutralization of non-VOC and 501Y.V2 VOC variants using plasma from COVID-19 patients in South Africa. It found that plasma from individuals infected during the first wave effectively neutralized the first-wave virus variant, while plasma from those infected in the second wave effectively neutralized the 501Y.V2 variant.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Erik Volz et al.

Summary: Genetic and testing data from England indicate that the SARS-CoV-2 variant B.1.1.7 has a transmission advantage over other lineages, showing a rapid expansion during autumn 2020. Analysis of S gene target failures (SGTF) in community-based diagnostic PCR testing suggests that B.1.1.7 is more transmissible than non-variant of concern lineages and has a significant transmission advantage, with a reproduction number 50% to 100% higher. Additionally, cases of B.1.1.7 appear to include a larger share of under 20-year-olds compared to non-variant cases.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Leonidas Stamatatos et al.

Summary: The study found that vaccination of both previously infected individuals and those who were not infected resulted in increased neutralizing antibody titers, with previously infected individuals showing a greater boost in neutralizing titers. Vaccination of naive individuals also elicited cross-neutralizing responses, but at lower titers.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

Nuno R. Faria et al.

Summary: A new variant of concern, P.1, with 17 mutations including three spike protein mutations associated with increased binding to human ACE2 receptors, emerged in Manaus, Brazil between November 2020 and January 2021. Molecular analysis suggests P.1 may be 1.7- to 2.4-fold more transmissible and that previous infection may provide 54 to 79% protection against P.1 infection compared to other lineages. Enhanced global genomic surveillance of such variants is crucial for pandemic response.

SCIENCE (2021)

Add to Collection

Article Cell Biology

Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

Alison Tarke et al.

Summary: By studying T cell responses in 99 convalescent COVID-19 cases, we identified various HLA-restricted epitopes derived from SARS-CoV-2 and observed distinct patterns of immunodominance. The epitopes were combined into megapools to facilitate the identification and quantification of virus-specific CD4(+) and CD8(+) T cells.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Alba Grifoni et al.

CELL (2020)

Add to Collection

Editorial Material Multidisciplinary Sciences

Avoiding pitfalls in the pursuit of a COVID-19 vaccine

Lynne Peeples

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection

Article Biochemistry & Molecular Biology

NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data

Birkir Reynisson et al.

NUCLEIC ACIDS RESEARCH (2020)

Add to Collection

Article Allergy

Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

Annarosa Soresina et al.

PEDIATRIC ALLERGY AND IMMUNOLOGY (2020)

Add to Collection

Review Immunology

COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases

D. Baker et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Tyler N. Starr et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Carolyn Rydyznski Moderbacher et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Julian Braun et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Nina Le Bert et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Jose Mateus et al.

SCIENCE (2020)

Add to Collection

Article Immunology

Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein

Andrew P. Ferretti et al.

IMMUNITY (2020)

Add to Collection

Review Multidisciplinary Sciences

Animal models for COVID-19

Cesar Munoz-Fontela et al.

NATURE (2020)

Add to Collection

Article Immunology

Broad and strong memory CD4+and CD8+T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Yanchun Peng et al.

NATURE IMMUNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Hematology

SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein

Michael D. Keller et al.

BLOOD (2020)

Add to Collection

Article Immunology

Cross-reactive memory T cells and herd immunity to SARS-CoV-2

Marc Lipsitch et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

Article Psychiatry

Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia

Sheila M. Dowd et al.

WORLD JOURNAL OF PSYCHIATRY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

IEDB-AR: immune epitope database-analysis resource in 2019

Sandeep Kumar Dhanda et al.

NUCLEIC ACIDS RESEARCH (2019)

Add to Collection

Article Multidisciplinary Sciences

VACCINOLOGY Structural topology defines protective CD8+ T cell epitopes in the HIV proteome

Gaurav D. Gaiha et al.

SCIENCE (2019)

Add to Collection

Article Biochemistry & Molecular Biology

The Immune Epitope Database (IEDB): 2018 update

Randi Vita et al.

NUCLEIC ACIDS RESEARCH (2019)

Add to Collection

Article Cell Biology

Is It Possible to Develop a Universal Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine

Florian Krammer et al.

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin

Michael B. Doud et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Article Immunology

NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data

Vanessa Jurtz et al.

JOURNAL OF IMMUNOLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells

Samantha Reiss et al.

PLOS ONE (2017)

Add to Collection

Article Cell Biology

Immune history profoundly affects broadly protective B cell responses to influenza

Sarah F. Andrews et al.

SCIENCE TRANSLATIONAL MEDICINE (2015)

Add to Collection

Article Biochemistry & Molecular Biology

Cellular immune correlates of protection against symptomatic pandemic influenza

Saranya Sridhar et al.

NATURE MEDICINE (2013)

Add to Collection

Article Biochemistry & Molecular Biology

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

Tom M. Wilkinson et al.

NATURE MEDICINE (2012)

Add to Collection

Article Biochemistry & Molecular Biology

ViPR: an open bioinformatics database and analysis resource for virology research

Brett E. Pickett et al.

NUCLEIC ACIDS RESEARCH (2012)

Add to Collection

Article Multidisciplinary Sciences

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population

Jason A. Greenbaum et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)

Add to Collection

Article Multidisciplinary Sciences

Hemagglutinin Receptor Binding Avidity Drives Influenza A Virus Antigenic Drift

Scott E. Hensley et al.

SCIENCE (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.